| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-11-10 | 002755 | 奥赛康 | 16.68 | 17.00 | 283.56 | 招商证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司西安北大街证 | 公司南京分公司 | | | | | | | | 券营业部 | | | 2025-11-10 | 002755 | 奥赛康 | 16.68 | 25.00 | 417.00 | 招商证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司西安北大街证 | 公司南京分公司 | | | | | | | | 券营业部 | | | 2025-11-10 | 002755 | 奥赛康 | 16.68 | 14.00 | 233.52 | 机构专用 | 华泰证券股份有限 | | | | | | | | | 公司南京分公司 | ...

11月5日，奥赛康大宗交易成交100万股，成交额1720万元，占当日总成交额的5.36%，成交价17.2元， 较市场收盘价19.05元折价9.71%。 ...

11月3日，奥赛康大宗交易成交269.34万股，成交额4718.84万元，占当日总成交额的10.96%，成交价 17.52元，较市场收盘价19.6元折价10.61%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | (万股/万份) | (万元) | | | | 2025-11-03 | 002755 | 奥赛康 | 17.52 | 11.50 | 201.48 | 机构专用 | 华泰证券股份有限 | | | | | | | | | 公司南京分公司 | | 2025-11-03 | 002755 | 與賽康 | 17.52 | 11.50 | 201.48 | 机构专用 | 华泰证券股份有限 | | | | | | | | | 公司南京分公司 | | 2025-11-03 | 002755 | 奥赛康 | 17.52 | 24.00 | 420.48 | 招商证券股份有限 | 华泰证券股份有限 | | | | | | ...

Core Insights - As of October 31, a total of 129 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is CITIC Bo, which has seen net buying for 14 trading days [1] - Other notable stocks with significant consecutive net inflows include Daimai Co., Weichuang Electric, Foster, Zhenhua Technology, Honghua Digital, Aosaikang, Dongcheng Pharmaceutical, and Huace Navigation [1]

Group 1 - The core viewpoint of the news is that Aosaikang's stock price increased by 5.12%, reaching 19.09 CNY per share, with a total market capitalization of 17.719 billion CNY [1] - Aosaikang Pharmaceutical Co., Ltd. is located in Jiangning Science Park, Nanjing, and was established on December 24, 1996, with its listing date on May 15, 2015 [1] - The company's main business involves the research, production, and sales of drugs, with revenue composition as follows: oncology drugs 38.28%, anti-infection drugs 24.74%, chronic disease drugs 21.65%, digestive drugs 12.33%, and others 2.34% [1] Group 2 - From the perspective of fund holdings, Penghua Fund has one fund heavily invested in Aosaikang, specifically the Penghua Health and Environmental Mixed Fund, which reduced its holdings by 39,100 shares in the third quarter [2] - The current number of shares held by the fund is 283,700, accounting for 4.89% of the fund's net value, making it the third-largest holding [2] - The fund has achieved a year-to-date return of 32.38% and a one-year return of 27.59%, with a total fund size of 120 million CNY [2]

Core Insights - Osai Kang (002755.SZ) reported its Q3 2025 results, revealing that 21 institutional investors hold a total of 747 million shares, accounting for 80.45% of the company's total equity [1] - The top ten institutional investors collectively hold 80.04% of the shares, with a slight decrease of 0.39 percentage points compared to the previous quarter [1] Institutional Holdings - In the public fund sector, six funds increased their holdings, including Yongying Medical Innovation Mixed Fund A and Huaxia Smart Selection Mixed Fund A, with an increase rate of 1.22% [2] - Three public funds reduced their holdings, including Guolian Medical Consumption Mixed Fund A, with a slight decrease in holding percentage [2] - Six new public funds were disclosed this period, including Yongying Ruixin Mixed Fund A and Huaxia Dingrong Bond Fund A [2] - A total of 194 public funds were not disclosed this period, including Penghua Medical Technology Stock A and Southern CSI 1000 ETF [2] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.31% [2] - One foreign fund, Zhongyi Weiye Holdings Limited, reduced its holdings by 0.21% [2]

Core Insights - The company reported a total operating revenue of 1.434 billion yuan and a net profit attributable to shareholders of 223 million yuan for Q3 2025 [1] - The net cash inflow from operating activities was 602 million yuan [1] Financial Performance - The latest debt-to-asset ratio is 26.25%, an increase of 5.29 percentage points compared to the same period last year [3] - The latest gross profit margin is 79.80%, which is a decrease of 1.89 percentage points from the previous quarter and a decrease of 2.03 percentage points from the same period last year [3] - The latest return on equity (ROE) is 6.97% [3] - The diluted earnings per share (EPS) is 0.24 yuan [3] - The total asset turnover ratio is 0.34 times, a decrease of 0.03 times compared to the same period last year, representing a year-on-year decline of 8.70% [3] - The inventory turnover ratio is 1.79 times [3] Shareholder Structure - The number of shareholders is 27,200, with the top ten shareholders holding a total of 743 million shares, accounting for 80.04% of the total share capital [3] - The top ten shareholders and their holdings are as follows: - Nanjing Aosaikang Investment Management Co., Ltd.: 34.2% - Zhongyi Weiye Holdings Co., Ltd.: 12.7% - Jiangsu Suyang Investment Industry Co., Ltd.: 12.6% - Weirui Development Co., Ltd.: 12.2% - Nanjing Haiji Investment Management Co., Ltd.: 2.94% - Industrial Bank Co., Ltd. - Yongying Medical Innovation Mixed Fund: 2.26% - CITIC Bank Co., Ltd. - Yongying Ruixin Mixed Fund: 1.01% - Hong Kong Central Clearing Limited: 0.82% - Zheshang Bank Co., Ltd. - Yongying Stable Enhanced Bond Fund: 0.62% - Bank of China Co., Ltd. - E Fund Healthcare Industry Mixed Fund: 0.62% [3]

Core Viewpoint - The company, Beijing Osai Kang Pharmaceutical Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2][7]. Financial Data - The third-quarter financial report has not been audited [3][8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for this quarter [3]. Board Meeting - The seventh board of directors held its fifth meeting on October 28, 2025, where all nine directors attended, and the meeting complied with relevant laws and regulations [7]. - The board unanimously approved the third-quarter report with a voting result of 9 in favor, 0 against, and 0 abstentions [7][8]. Shareholder Information - The report includes details on the total number of ordinary shareholders and the shareholding status of the top ten shareholders [4]. - There are no changes in the borrowing or returning of shares by major shareholders due to transfer and financing activities [5]. Other Important Matters - The company confirms that there are no other significant matters to disclose in this quarter's report [5].

Core Insights - The company reported a revenue of 1,433,894,250.94 yuan for the first three quarters of 2025, representing a year-on-year growth of 3.57% [2] - The net profit attributable to shareholders of the listed company was 223,314,336.76 yuan, showing a significant year-on-year increase of 75.81% [2] Financial Performance - Revenue for the first three quarters of 2025: 1,433.89 million yuan [2] - Year-on-year revenue growth: 3.57% [2] - Net profit for the first three quarters of 2025: 223.31 million yuan [2] - Year-on-year net profit growth: 75.81% [2]

Core Insights - The company reported a revenue of 1.434 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 3.57% [1] - The net profit attributable to shareholders reached 223 million yuan, showing a significant year-on-year increase of 75.81% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 186 million yuan, reflecting a year-on-year growth of 81.89% [1]